Eloxatin (oxaliplatin) is primarily used in combination with which other treatments for colorectal cancer?

Eloxatin, known generically as oxaliplatin, is primarily utilized in combination with 5-fluorouracil (5-FU) and leucovorin for the treatment of colorectal cancer. This combination is part of the FOLFOX regimen, which stands for Folinic acid (leucovorin), Fluorouracil, and Oxaliplatin.

5-FU is a cornerstone chemotherapy drug used in many gastrointestinal malignancies, including colorectal cancer, and enhances the effectiveness of oxaliplatin. Leucovorin serves as a "rescue" agent that increases the efficacy of 5-FU, particularly in interfering with cancer cell growth and survival. The synergy between these drugs allows for improved therapeutic outcomes compared to using each agent alone.

The other options involve drug combinations that do not have established roles in the treatment of colorectal cancer, making them less relevant in this context. Thus, the combination of Eloxatin with 5-FU and leucovorin is critical in the management of colorectal cancer, supporting the decision to choose that combination as the correct answer.